caa a22 4500 46911911X CHVBK 20180323133133.0 cr unu---uuuuu 170328e19921001xx s 000 0 eng 10.1007/BF02245475 doi (NATIONALLICENCE)springer-10.1007/BF02245475 A comparison of trazodone and fluoxetine: implications for a serotonergic mechanis of antidepressant action [Elektronische Daten] [Gerard Marek, Christopher McDougle, Lawrence Price, Lewis Seiden] Trazodone is an atypical antidepressant drug that is commonly referred to as a serotonin (5-hydroxytryptamine; 5-HT) uptake inhibitor. However, the most potent pharmacological effect of trazodone appears to be antagonist action at 5-HT2/1C receptors. This is in contrast to fluoxetine, for which inhibition of 5-HT uptake is the most potent pharmacological action. The effects of trazodone and fluoxetine on several antidepressant drug screens are mediated by antagonist action at 5-HT2 receptors and inhibition of 5-HT uptake, respectively. While fluoxetine is an effective agent for the treatment of major depression, obsessive-compulsive disorder (OCD) and panic disorder, trazodone does not appear to be effective in the treatment of OCD and panic disorder. In addition, trazodone and fluoxetine differ in humans with respect to their effects on sleep and weight. Taken together, the preclinical and clinical data suggest that trazodone acts as an antidepressant via antagonist action at 5-HT2/1C receptors, while fluoxetine likely acts as an antidepressant via inhibition of 5-HT uptake. Springer-Verlag, 1992 Trazodone nationallicence Fluoxetine nationallicence 5-HT2 antagonists nationallicence 5-HT uptake inhibitors nationallicence Serotonin nationallicence Atypical antidepressants nationallicence Marek Gerard Department of Psychiatry, Ribicoff Research Facilities, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, Yale University School of Medicine, 34 Park Street, 06519, New Haven, CT, USA aut McDougle Christopher Department of Psychiatry, Ribicoff Research Facilities, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, Yale University School of Medicine, 34 Park Street, 06519, New Haven, CT, USA aut Price Lawrence Department of Psychiatry, Ribicoff Research Facilities, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, Yale University School of Medicine, 34 Park Street, 06519, New Haven, CT, USA aut Seiden Lewis Department of Pharmacological and Physiological Sciences, The University of Chicago, 947 East 58th Street, 60637, Chicago, IL, USA aut Psychopharmacology Springer-Verlag 109/1-2(1992-10-01), 2-11 0033-3158 109:1-2<2 1992 109 213 https://doi.org/10.1007/BF02245475 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245475 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Marek Gerard Department of Psychiatry, Ribicoff Research Facilities, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, Yale University School of Medicine, 34 Park Street, 06519, New Haven, CT, USA aut NATIONALLICENCE 700 1- McDougle Christopher Department of Psychiatry, Ribicoff Research Facilities, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, Yale University School of Medicine, 34 Park Street, 06519, New Haven, CT, USA aut NATIONALLICENCE 700 1- Price Lawrence Department of Psychiatry, Ribicoff Research Facilities, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, Yale University School of Medicine, 34 Park Street, 06519, New Haven, CT, USA aut NATIONALLICENCE 700 1- Seiden Lewis Department of Pharmacological and Physiological Sciences, The University of Chicago, 947 East 58th Street, 60637, Chicago, IL, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 109/1-2(1992-10-01), 2-11 0033-3158 109:1-2<2 1992 109 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer